drugset / Trial / NCT05263050
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
Timeline
- Start
- 2022-01-21
- Primary completion
- 2026-12
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 20 mg | — |
| Subject | Cabozantinib | Small molecule | 40 mg | — |
| Subject | Cabozantinib | Small molecule | 60 mg | — |
| Background | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |